updated 9/8/2010 9:16:10 AM ET 2010-09-08T13:16:10

SEATTLE, Sept. 8, 2010 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) is pleased to announce the following appointment to its Board of Directors:

Lynn M. DePippo, Founder and Managing Partner, Sherbrook Capital Management. Previous appointments include Portfolio Manager Small Cap Equities at Citibank, Senior Investment Analyst at The Kaufmann Fund, NY, and Healthcare Services Analyst at Kidder Peabody and Company, N.Y.

"We are extremely pleased to welcome Lynn to the TapImmune Board," said Dr. Glynn Wilson, Chairman and CEO. "Lynn's experience in the financing and growth of healthcare companies will be invaluable to the next phase of the growth of TapImmune."

TapImmune is also pleased to announce the formation of its Advisory Team to support it recently announced collaborative agreements with the Mayo Clinic in Breast Cancer and Smallpox and its other preclinical  and clinical programs on its TAP technology. Initial appointments are:

Dr. Martin "Mac" Cheever, Director of Solid Tumor Research Program, Fred Hutchinson Cancer Research Center, Seattle.  Dr. Cheever is internationally renowned for his contributions to cancer immunotherapy and for moving "cutting edge" technologies from the lab into the clinic. He co-founded vaccine company Corixa, Seattle, WA and has been involved on the clinical development of breast cancer vaccines. He is a consultant to the National Cancer Institute on priorities for immunotherapy.

Dr. Roopa Srinivasan, has extensive experience in the preclinical development of biological therapeutics including antibodies, vaccines and gene therapy products. She was formerly Head and Program Leader, Tumor Immunology at CancerVax Corporation and Associate Director, Preclinical Development at Pain Therapeutics. She has a background in the cellular immunology of infectious disease and was a Research Associate, Department of Immunology, Sloan-Kettering Cancer Center, NY.

Mark A. Reddish, has broad experience in preclinical and clinical development and product manufacturing. He was formerly Vice President, Product Development and Principal Investigator Biodefense at ID Biomedical, Bothell, WA and was Senior Director for R&D at Biomira Inc, Edmonton, Alberta, with responsibility for the preclinical development of their therapeutic cancer vaccine program. 

"We welcome these accomplished scientists to our new Advisory Team which will be an integral part of our process as we move our platform technology into the clinic in both cancer and infectious disease," said Glynn Wilson. "We plan to add additional Advisory Team members as our development programs advance. The strength of our technical and clinical program is also reinforced by our collaborators, Keith L. Knutson, MD, and Gregory Poland MD at the Mayo Clinic, and Dr. John Fulkerson at Aeras Global TB Vaccine Foundation."

About Tapimmune Inc.

Taplmmune Inc. is a biotechnology company specializing in the development of innovative cell based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidate, the AdhTAP vaccine is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development AdhTAP for the commencement of clinical manufacturing and toxicology studies. The Company is also developing TAP-based prophylactic vaccines. As a vaccine component, the TAP technology has the potential to significantly improve the efficacy of current prophylactic vaccines and enhance the creation of new ones in the fight against pandemic infectious diseases.

The TapImmune Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3877

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.71%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com